1142 PROTEOMIC RESEARCH FOR DIAGNOSTIC MARKERS: INCREASED EXPRESSION OF S100A8/9 IS ASSOCIATED WITH DISEASE PROGRESSION AND CANCER-SPECIFIC SURVIVAL IN BLADDER CANCER

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Kazumasa Matsumoto ◽  
Yuichi Satoh ◽  
Takefumi Satoh ◽  
Ken-ichi Tabata ◽  
Sho Minami ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Diagnostic Markers ◽  
Cancer Specific Survival ◽  
Proteomic Research

scholarly journals Expression of MMP28 in bladder cancer tissue microarray and its clinical significance

2019 ◽  
Author(s):  
Wang Heng ◽  
Wu Junxiu ◽  
Chen Xinpeng ◽  
Zhang Qi ◽  
Zhao Tingxiao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Clinical Significance ◽  
Histological Grade ◽  
Expression Patterns ◽  
Lymphatic Invasion ◽  
Cancer Tissue ◽  
Cancer Specific Survival ◽  
Stage Disease ◽  
Bladder Cancer Tissue

Abstract Background: The aim of this study was to explore the expression pattern and prognostic value of MMP-28 for bladder cancer and analyze its relationship with the clinicopathological features of human bladder cancer. Methods: Immunohistochemical staining for MMP28 was performed in 491 archived radical bladder cancer resection and 80 normal specimens. The immunoreactivity of these proteins was correlated to evaluate their clinical significance as prognostic factors. Results: Protein level of MMP-28 was up-regulated in bladder cancer compared with adjacent non-tumor tissues. The increased expression of MMP-28 was significantly associated with high histological grade, lymph node metastasis, lymphatic invasion and distant metastasis (P<0.05). High expression of MMP-28 was also associated with greater risk of disease progression and decreased chance of cancer-specific survival. Further analysis suggested that MMP-28 was related with decreased overall survival. Conclusions: MMP-28 could be used as an effective marker for tumor diagnosis and predict tumor progression in bladder cancer. The expression patterns of MMP-28 interaction correlated well with the pathological stage, disease progression and tumor-specific survival. The finding may help identify more biologically aggressive carcinomas which could aid in patients who benefit from more intensive adjuvant therapy.

scholarly journals Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

2011 ◽  
Vol 2 (4) ◽  
pp. 679-684 ◽  
Author(s):  
PILDU JEONG ◽  
YUN-SOK HA ◽  
IN-CHANG CHO ◽  
SEOK-JOONG YUN ◽  
EUN SANG YOO ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Preoperative Serum Gamma-Glutamyltransferase as a Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Shiqiang Su ◽  
Lizhe Liu ◽  
Chao Sun ◽  
Yanhua Nie ◽  
Hong Guo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Elevated Serum ◽  
Disease Free Survival ◽  
Prognostic Models ◽  
Lymph Node Status ◽  
Cancer Specific Survival ◽  
Gamma Glutamyltransferase ◽  
Preoperative Serum

BackgroundSerum gamma-glutamyltransferase (GGT) has been reported to be correlated with survival in a variety of malignancies. However, its effect on patients with bladder cancer (BC) treated by radical cystectomy has never been evaluated.Patients and MethodsWe retrospectively evaluated 263 patients who underwent radical surgery in our center. Baseline features, hematologic variables, and follow-up data were obtained. The endpoints included overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). The relationship between GGT and survival were evaluated.ResultsThe median follow-up period for all patients was 34.7 (22.9-45.9) months. At the last follow-up, 67 patients died, 51 patients died of cancer, 92 patients experienced disease recurrence. Patients with an elevated serum GGT had a higher rate of pT3-T4 tumors. Patients with a higher preoperative serum GGT had a lower rate of OS, CSS and DFS (P &lt; 0.001 for all). Multivariate analysis identified that preoperative serum GGT was independent predictor of OS (HR: 3.027, 95% CI: 1.716-5.338; P &lt; 0.001), CSS (HR: 2.115, 95% CI: 1.093-4.090; P = 0.026), DFS (HR: 2.584, 95% CI: 1.569-4.255; P &lt; 0.001). Age, diabetes history, pathologic T stage, and lymph node status also were independent predictors of prognosis for BC patients.ConclusionsOur results indicated that preoperative serum GGT was an independent prognosis predictor for survival of BC patients after radical cystectomy, and can be included in the prognostic models.

Validation of a 5-gene expression panel for predicting disease progression in T1 highgrade bladder cancer

2018 ◽  
Vol 17 (10) ◽  
pp. e2501
Author(s):  
C.A. Sieverink ◽  
A.G. Van Der Heijden ◽  
L. Mengual ◽  
M. Ingelmo-Torres ◽  
M.J. Ribal ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bladder Cancer ◽  
Disease Progression

Impact of equal access healthcare on race disparities in bladder cancer.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 399-399
Author(s):  
Nikhil V. Kotha ◽  
Abhishek Kumar ◽  
Edmund M. Qiao ◽  
Daniel R. Cherry ◽  
Vinit Nalawade ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Healthcare System ◽  
Equal Access ◽  
Disease Stage ◽  
Seer Database ◽  
Cancer Specific Survival ◽  
Black Patients ◽  
Black Veterans ◽  
Multivariable Models ◽  
White Patients

399 Background: Outcomes in bladder cancer are disproportionately worse for black patients compared to white patients. We hypothesize these disparities arise in part due to differences in access to healthcare and therefore may be mitigated in an equal access healthcare system, such as the Veterans Affairs’ (VA) system. Here, we examine outcomes by race for patients with bladder cancer within the VA system and then compare these outcomes to those in the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We performed a retrospective cohort study using VA Informatics and Computing Infrastructure (VINCI) and SEER. We included all patients diagnosed with bladder cancer, American Joint Committee on Cancer (AJCC) stage 0-4 diagnosed between 2000 and 2018. Endpoints of overall survival (OS), bladder cancer-specific survival (BCS), and non-bladder cancer-specific survival (NCS) were evaluated in multivariable Cox and Fine-Gray models. Results: Using the VA dataset, we identified 36322 veterans (9.0% black, 91.0% white) with bladder cancer. Black veterans were more likely to have more comorbidities, reside in zip codes with lower median income and education levels, and present with higher stage disease (AJCC stages 2-4) than white veterans (23.3% vs 19%). In multivariable models accounting for disease stage among other covariables, there were no statistically significant differences in any survival endpoint (Table). Using the SEER dataset, we identified 130998 patients (5.9% black, 94.1% white) with bladder cancer. In similar multivariable models, SEER’s black patients had statistically significant inferior outcomes in all survival endpoints compared to SEER’s white patients (Table). Conclusions: While racial disparities for patients with bladder cancer in the SEER database were observed, no differences in survival outcomes between black and white patients were observed in the VA healthcare system. Of note, black veterans presented with more advanced stage, suggesting a delay in diagnosis or a more aggressive cancer phenotype compared to white patients. Our findings underscore the need to bridge healthcare disparities across diverse racial groups. Our study highlights the beneficial impact of an equal access healthcare system in reducing financial and social barriers to healthcare to counteract racial health disparities. Further research is required to delineate these disparities and guide appropriate screening strategies. [Table: see text]

Sub-staging specific differences in recurrence-free, progression-free and cancer-specific survival for patients with T1 bladder cancer: a systematic review and meta-analysis

2020 ◽  
Author(s):  
GuanQiu Chen ◽  
Tao Yang ◽  
Pu Zhang ◽  
Meng-Zhao Zhang ◽  
Bo Yang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Significance ◽  
Treatment Strategies ◽  
Progression Free Survival ◽  
Staging System ◽  
Cochrane Library ◽  
Significant Prognostic Factor ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Significant Difference

Abstract Background: The efficiency of the T1 sub-staging system on categorizing bladder cancer (BC) patients into subgroups with different clinical outcomes was unclear. We summarized relevant evidences, including recurrence-free survival (RFS), progression-free survival (PFS) and cancer-specific survival (CSS), to analyze the prognostic significance of T1 sub-stage.Methods: Systematic literature searches of MEDLINE, EMBASE and the Cochrane Library were performed. We pooled data on recurrence, progression, and CSS from 35 studies.Results: The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) indicated the difference in RFS between T1a sub-stage and T1b sub-stage (HR1.28, 95%CI 1.14-1.43). The significant difference was observed in PFS between the two arms (HR 2.18, 95%CI 1.95-2.44). Worse CSS was found in T1b patients than T1a patients (HR 1.45, 95%CI 1.28-1.64).Conclusions: T1 sub-staging system based on the invasion depth into muscularis mucosae (MM) can be a significant prognostic factor for RFS, PFS, and CSS of patients with T1-BC. Urologists and pathologists are encouraged to work together to give a precise sub-stage classification of T1-BC, and T1 sub-staging system should be a routine part of any histopathological report when possible. Different treatment strategies need to be developed for both T1a-BC and T1b-BC.

scholarly journals A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

2011 ◽  
Vol 17 (5-6) ◽  
pp. 478-485 ◽  
Author(s):  
Wun-Jae Kim ◽  
Seon-Kyu Kim ◽  
Pildu Jeong ◽  
Seok-Joong Yun ◽  
In-Chang Cho ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document